| abstract |
Disclosed is a capsule which comprises: (i) 1 or 2 coated tablet(s) comprising acetylsalicylic; (ii) 1 or 2 coated tablet(s) comprising simvastatin or 1 or 2 coated tablet(s) comprising pravastatin or a pharmaceutically acceptable salt thereof; and (iii) 1, 2 or 3 coated tablet(s) comprising lisinopril or a hydrated form, 1, 2 or 3 coated tablet(s) comprising ramipril, or 1, 2 or 3 coated tablet(s) comprising perindopril or a pharmaceutically acceptable salt thereof, The amount of acetylsalcilic acid is from 40.5 to 200 mg. The amount of simvastatin or pravastatin is from 20 to 80 mg. The amount of lisinopril, ramipril or perindopril is from 5 to 40 mg, 2.5 to 20 mg or 2 to 16 mg respectively. The acetylsalicylic acid tablets are coated with a partially hydrolysed polyvinyl alcohol comprising film. The simvastatin tablets are coated with a hydroxypropylmethyl cellulose comprising film. The pravastatin or pharmaceutically acceptable salt tablets are coated with a hydroxypropylmethyl cellulose comprising film. The lisinopril or hydrated form tablets are coated with a partially hydrolysed polyvinyl alcohol comprising film. The ramipril tablets are coated with a partially hydrolysed polyvinyl alcohol comprising film. The perindopril or pharmaceutically acceptable salt tablets are coated with a partially hydrolysed polyvinyl alcohol comprising film. Also disclosed is the use of the capsule in the manufacture of a medicament for the prevention of cardiovascular diseases in high risk populations. |